Distribution of Stage I Lung Cancer Growth Rates Determined with Serial Volumetric CT Measurements

Purpose: To retrospectively determine the distribution of stage I lung cancer growth rates with serial volumetric computed tomographic (CT) measurements.

Materials and Methods: This study was institutional review board approved and HIPAA compliant. The informed consent requirement was waived. Patients (n = 149) with stage I lung cancer who underwent two pretreatment CT examinations 25 or more days apart were identified. At the first and last examinations, tumor perimeters were manually inscribed by using software tools and the cross-sectional area was calculated. To calculate tumor volume, the summed areas were multiplied by the section increment and a formula was applied to reduce partial volume effects. Doubling time (DT) was calculated by using the volume and interscanning interval. The percentages of tumors that would surpass volume increase thresholds of 5%–25% for detectable growth at different time intervals were calculated. Age at diagnosis was compared with the reciprocal of DT, time interval between CT examinations, and initial tumor volume by using Pearson correlation. P < .05 denoted statistical significance.

Results: Lung cancer was stage IA in 99 patients and stage IB in 50. Median patient age was 72 years, and median interscanning interval was 130 days. Median tumor volumes were 3000 and 6213 mm3 at the first and last examinations, respectively. Median DT was 207 days; 21 tumors did not increase in volume between examinations. The interscanning interval required for 90% of growing tumors to surpass the growth threshold ranged from 8 weeks (5% threshold) to 37 weeks (25% threshold). Fifty-three percent of growing tumors would surpass the 25% threshold at 8 weeks, and 95% would surpass it at 1 year. Age at diagnosis was negatively correlated with growth rate (P = .047); there was no correlation between growth rate and either age at diagnosis or interscanning interval.

Conclusion: At serial volumetric CT measurements, there was wide variability in growth rates. Some biopsy-proved cancers decreased in volume between examinations.

© RSNA, 2006

References

  • 1 Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111(6): 1710–1717. Crossref, MedlineGoogle Scholar
  • 2 Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96(3):440–447. [Published correction appears in J Thorac Cardiovasc Surg 1989;97(3):350.] Google Scholar
  • 3 Sone S, Takashime S, Li P, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998;351:1242–1245. Crossref, MedlineGoogle Scholar
  • 4 Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99–105. Crossref, MedlineGoogle Scholar
  • 5 Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201:798–802. LinkGoogle Scholar
  • 6 Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: 5-year prospective experience. Radiology 2005;235:259–265. LinkGoogle Scholar
  • 7 Garland LH, Coulson W, Wollin E. The rate of growth and apparent duration of untreated primary bronchial carcinoma. Cancer 1963;16:694–701. Crossref, MedlineGoogle Scholar
  • 8 Spratt JS Jr, Spjut HJ, Roper CL. The frequency distribution of the rates of growth and the estimated duration of primary pulmonary carcinomas. Cancer 1963;16:687–693. Crossref, MedlineGoogle Scholar
  • 9 Steele JD, Buell P. Asymptomatic solitary pulmonary nodules, host survival, tumor size, and growth rate. J Thorac Cardiovasc Surg 1973;65:140–151. Crossref, MedlineGoogle Scholar
  • 10 Weiss W. Tumor doubling time and survival of men with bronchogenic carcinoma. Chest 1974;65:3–8. Crossref, MedlineGoogle Scholar
  • 11 Weiss W, Boucot KR, Cooper DA. Growth rate in the detection and prognosis of bronchogenic carcinoma. JAMA 1966;198:1246–1252. Crossref, MedlineGoogle Scholar
  • 12 Aoki T, Nakata H, Watanabe H, et al. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol 2000;174:763–768. Crossref, MedlineGoogle Scholar
  • 13 Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000;73:1252–1259. Crossref, MedlineGoogle Scholar
  • 14 Winer-Muram HT, Jennings SG, Tarver RD, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002;223:798–805. LinkGoogle Scholar
  • 15 Tan BB, Flaherty KR, Kazerooni EA, Iannettoni MD. The solitary pulmonary nodule. Chest 2003;123(1 suppl):89S–96S. Crossref, MedlineGoogle Scholar
  • 16 Yankelevitz DF, Henschke CI. Does 2-year stability imply that pulmonary nodules are benign? AJR Am J Roentgenol 1997;168:325–328. Crossref, MedlineGoogle Scholar
  • 17 Yankelevitz DF, Reeves AP, Kostis WJ, Zhao B, Henschke CL. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology 2000;217:251–256. LinkGoogle Scholar
  • 18 Yankelevitz DF, Gupta R, Zhao B, Henschke CI. Small pulmonary nodules: evaluation with repeat CT—preliminary experience. Radiology 1999;212:561–566. LinkGoogle Scholar
  • 19 Winer-Muram HT, Jennings SG, Meyer CA, et al. Effect of varying CT section width on volumetric measurement of lung tumors and application of compensatory equations. Radiology 2003;229:184–194. LinkGoogle Scholar
  • 20 Jennings SG, Winer-Muram HT, Tarver RD, Farber MO. Lung tumor growth assessment with CT: comparison of diameter and cross-sectional area with volume measurements. Radiology 2004;231:866–871. LinkGoogle Scholar
  • 21 Kostis WJ, Yankelevitz DF, Reeves AP, Fluture SC, Henschke CI. Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT. Radiology 2004;231:446–452. LinkGoogle Scholar
  • 22 Garland LH. The rate of growth and natural duration of primary bronchial cancer. Am J Roentgenol Radium Ther Nucl Med 1966;96:604–611. Crossref, MedlineGoogle Scholar
  • 23 Weiss W. Peripheral measurable bronchogenic carcinoma: growth rate and period of risk after therapy. Am Rev Respir Dis 1971;103:198–208. MedlineGoogle Scholar
  • 24 Nathan MH, Collins VP, Adams RA. Differentiation of benign and malignant pulmonary nodules by growth rate. Radiology 1962;79:221–232. LinkGoogle Scholar
  • 25 Filderman AE, Shaw C, Matthay RA. Lung cancer in the elderly. Clin Geriatr Med 1986;2:363–383. Crossref, MedlineGoogle Scholar
  • 26 Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059–1068. Crossref, MedlineGoogle Scholar
  • 27 Libby DM, Smith JP, Altorki NK, Pasmantier MW, Yankelevitz D, Henschke CI. Managing the small pulmonary nodule discovered by CT. Chest 2004;125:1522–1529. Crossref, MedlineGoogle Scholar
  • 28 Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21:2574–2582. Crossref, MedlineGoogle Scholar

Article History

Published in print: 2006